The presence of anti-human leukocyte antigen (anti-HLA) antibodies defines transplant candidates as sensitised, a condition that affects access to transplantation, increasing waiting times and mortality rates. Following transplantation, sensitised patients have higher risk of antibody-mediated rejection (AMR) and graft failure when their anti-HLA antibodies are specific to the donor (DSA). Not all DSAs are equally
The ENGAGE Initiative: Reshaping the Landscape of Kidney Transplantation for Sensitised Patients
